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Abstract
Background: Milk derived peptides have been identified as potential antihypertensive agents. The primary
objective was to investigate the effectiveness of IPP-rich milk protein hydrolysates (MPH) on reducing blood
pressure (BP) as well as to investigate safety parameters and tolerability. The secondary objective was to confirm or
falsify ACE inhibition as the mechanism underlying BP reductions by measuring plasma renin activity and
angiotensin I and II.
Methods: We conducted a randomized, placebo-controlled, double blind, crossover study including 70 Caucasian
subjects with prehypertension or stage 1 hypertension. Study treatments consisted of daily consumption of two
capsules MPH1 (each containing 7.5 mg Isoleucine-Proline-Proline; IPP), MPH2 (each containing 6.6 mg Methionine-
Alanine-Proline, 2.3 mg Leucine-Proline-Proline, 1.8 mg IPP), or placebo (containing cellulose) for 4 weeks.
Results: In subjects with stage 1 hypertension, MPH1 lowered systolic BP by 3.8 mm Hg (P = 0.0080) and diastolic
BP by 2.3 mm Hg (P = 0.0065) compared with placebo. In prehypertensive subjects, the differences in BP between
MPH1 and placebo were not significant. MPH2 did not change BP significantly compared with placebo in stage I
hypertensive or prehypertensive subjects. Intake of MPHs was well tolerated and safe. No treatment differences in
hematology, clinical laboratory parameters or adverse effects were observed. No significant differences between
MPHs and placebo were found in plasma renin activity, or angiotensin I and II.
Conclusions: MPH1, containing IPP and no minerals, exerts clinically relevant BP lowering effects in subjects with
stage 1 hypertension. It may be included in lifestyle changes aiming to prevent or reduce high BP.
Trial registration: ClinicalTrials.gov NCT00471263
Background
High blood pressure (BP) is a controllable risk factor in
the development of cardiovascular conditions, and
therefore any food component with the ability to reduce
BP could contribute to the prevention or treatment of
cardiovascular diseases [1-3].
Milk-derived peptides have been identified as potential
antihypertensive agents. The best-characterized peptides
found in fermented or enzymatically treated milk are
Isoleucine-Proline-Proline (IPP), and Valine-Proline-Pro-
line (VPP). Over twenty five human studies have been
performed linking the consumption of products
containing both IPP and VPP with significant reductions
in BP [4-6]. Fifteen of the BP studies have been done in
Japanese subjects. Ten studies have been performed in
Caucasians, that is, in Finnish subjects [7-10], Dutch
subjects [11-14], Scottish subjects [15] and American
subjects [16].
Effective dosages range from 3.07 mg/d (1.60 mg IPP
and 1.47 mg VPP) to 52.5 mg/d (30 mg IPP and 22.5
mg VPP) [10,17]. Recently, casein hydrolysates with dif-
ferent bioactive peptide profiles were developed based
on their in vitro ACE inhibitory potential: MPH1 (or
tensVida™) and MPH2. The identified peptide contribut-
ing to ACE inhibitory effects in MPH1 is IPP, and those
in MPH2 are Methionine-Alanine-Proline (MAP), IPP,
and Leucine-Proline-Proline (LPP). In the ACE
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than MPH1.
An advantage is that these products contain a negligi-
ble amount of minerals contrasting with all other lacto-
tripeptide-based products tested so far [18-23].
Although the dosages of minerals in the sour milk are
much lower than those that were effective in lowering
BP in intervention trials, and placebo treatments were
controlled for mineral content, it is possible that the
minerals may have induced additive or synergistic BP
effects. To our knowledge, this is the first study per-
formed in Caucasian subjects using products with a neg-
ligible amount of minerals.
The primary objective of the study was to investigate
the effectiveness of MPHs on reducing BP as well as to
investigate safety parameters and tolerability in subjects
with prehypertension and stage 1 hypertension. The sec-
ondary objective was to obtain information on the
mechanism of action underlying the BP effects. The
dose chosen is somewhat higher than the lower doses
tested for similar products earlier in Japanese subjects,
in view of the fact that Caucasian subjects tend to show
a smaller blood pressure lowering toward lactotripeptide
treatment than Japanese [5,6].
Methods
Study participants
Male and female Caucasian subjects were recruited from
the pool of volunteers of TNO Quality of Life. After
being informed about the study, the subjects gave volun-
tary written informed consent. Health was assessed by
an interview on medical history, physical examination,
and routine laboratory tests on blood and urine. To
select subjects with prehypertension and stage 1 hyper-
tension, the classification according to JNC-7 was used
[24]: subjects with a systolic BP between 140 - 159 mm
Hg or a diastolic BP between 90 - 99 mm Hg were
assigned to ‘stage 1 hypertension’, and subjects with a
systolic BP between 120 - 139 mm Hg or a diastolic BP
between 80 - 89 mm Hg were designated ‘prehyperten-
sion’. BP was measured on three separate visits. Subjects
with a history of medical events or medication that may
have influenced the study outcome were excluded from
participation. Subjects who were on slimming, medically
prescribed, vegan, vegetarian or macrobiotic diet were
also excluded as were smokers and subjects using more
than 28 units (men) or 21 units (women) of alcohol per
week to exclude alcoholics. Pregnant or lactating
women were also excluded from participation. Eighty
healthy subjects were included in the study.
Study design
The study was designed as a randomized, placebo-
controlled, double blind, crossover study. Study treatments
were given to the subjects according to a Latin square
design. In view of the very short half-life of lactotripeptides
[25], no wash-out period was included between treat-
ments. The study was powered to detect a 3.5 mmHg sys-
tolic blood pressure difference between placebo and
treatment at an a of 0.05 (two-sided) and a b of 0.8.
Study protocol
Subjects visited the test facility of TNO Quality of Life
at three consecutive test days at the end of each treat-
m e n tp e r i o d .A tt h ef i r s tt w ot e s td a y s ,B Pm e a s u r e -
ments were performed two hours after the subjects had
their own habitual breakfast and the study substances at
home. At the third test day, subjects came in a fasted
state for collection of blood and spot-urine samples. No
alcohol and sports were allowed the day before the test
days, and no dairy products were allowed at breakfast
on the test days. During the study period, subjects were
instructed not to consume more than one portion of a
fermented dairy product per day.
The study was performed according to the ICH
Guideline for Good Clinical Practice (ICH topic E6,
adopted 01-05-1996 and implemented 17-01-1997) and
was approved by the independent Medical Ethics Com-
mittee METOPP (Tilburg, the Netherlands).
Study products
MPH1 and MPH2 were produced through hydrolysis of
glycomacropeptide and casein, respectively. Hydrolysis
was performed using a proline-specific endoprotease. The
nutritional properties, as well as the amounts of bioactive
peptides of the study products are presented in table 1.
Lactotripeptides were quantified as described in [26].
Study treatments
Study treatments were offered to the volunteers in cap-
sules, to exclude any pre-ingestion interference with
Table 1 Characteristics of study products
MPH 1 MPH 2 placebo
Protein 570.0 570.0 -
Fat 2.5 2.3 -
Carbohydrates 3.4 13.7 570
Na 3.1 0.9 -
Ca 5.9 1.0 -
K 2.5 34.3 -
Fibre - - 570
Ashes (%) 8 5 nd
Total Organic Solids (%) 89 75 nd
IPP 7.5 1.8 -
MAP - 6.6 -
LPP - 2.3 -
mg per capsule, unless indicated otherwise.
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of MPH1 or MPH2 or placebo during 4 weeks. Five
hundred mg hydrolysed protein was used per capsule
for each of the MPH treatments. The lactotripeptide
content per capsule was 7.5 mg IPP for MPH1, and 6.6
mg MAP, 2.3 mg LPP, and 1.8 mg IPP for MPH2. Sub-
jects received 2 capsules per day, and were instructed to
consume one capsule directly upon completion of
breakfast and one capsule directly upon completion of
dinner. Placebo treatment consisted of daily consump-
tion of 2 capsules, each of them filled with 500 mg cel-
lulose (food grade quality).
Blood pressure measurements
BP was measured between 2.5 and 3.5 h after ingestion
of the study substances using automated digital sphyg-
momanometry (OMRON IC). In brief, subjects rested
f o ra tl e a s t1 5m i na tr o o mt e m p e r a t u r e .T h eB Pc u f f
was placed around the upper left arm which was sup-
ported at the level of the heart while the subject sat in a
chair with the feet positioned flat on the floor and with
a straight back rested against the chair. The first mea-
surement was taken after three minutes rest. The sub-
ject was told not to move or speak. In total four
measurements were taken with one minute rest in
b e t w e e n .T h ea v e r a g eo ft h el a s tt h r e em e a s u r e m e n t s
was calculated.
Safety parameters
Clinical laboratory tests were performed at screening
and at the end of treatment and included hematology,
serum chemistry (liver enzymes, albumin, bilirubin,
urea, creatinin, cholesterol parameters, triacylglycerols,
glucose, minerals, blood sedimentation rate, and C-reac-
tive protein). Blood samples were obtained from the
antecubital vein of the forearm and collected in tubes
containing clot activator for serum and in tubes contain-
ing potassium ethylene diamine tetra acid (K3EDTA) for
plasma (Vacutainer Systems, Becton Dickinson, Ply-
mouth, UK). Blood was centrifuged for 15 min at ca.
2,000 × g at ca. 4°C within 15-30 min after collection,
and stored at -20°C until analysis. All biochemical deter-
minations in blood were performed at TNO Quality of
Life using Olympus AU400 analytical equipment and
reagents. Dipstick urinalysis was performed on the day
of collection to assess the presence of protein, glucose,
leucocytes, erythrocytes, nitrite, pH, ketones, bilirubin,
and urobilinogen. A microscopic inspection of sediment
was done if the dipstick test gave values above the nor-
mal range for leucocytes, blood or protein.
At the end of treatment, subjects indicated the pre-
sence or absence of a number of possible adverse effects
in a questionnaire using a 4-point scale from ‘not at all’
to ‘very often’. Symptoms included not feeling well,
headache, weakness, fatigue, nausea, vomiting, burping,
stomach-ache, bloating, flatulence, constipation, diar-
rhea, dry mouth, change of taste, cough, and skin
complaints.
Mechanistic parameters
For renin, blood was collected in Vacutainer® tubes con-
taining K3EDTA as anticoagulant and centrifuged
immediately (15 minutes at 2,000 × g and ca. 20°C).
Plasma was snap frozen in liquid nitrogen and stored at
-80°C. For angiotensin I and II, blood was collected in
Vacutainer® tubes containing K3EDTA as anticoagulant
and protease inhibitor buffer was added at an amount of
50 μL buffer/ml blood. The buffer consisted of (stock
100 mL): 4250 mg EDTA, 8.13 mg enalaprilate, 200 mg
neomycin, 0.5 mg o-phenantroline, 2% ethanol, 6 mg
renin inhibitor (Sigma, cat.nr. C9415). Samples were
centrifuged within 10 minutes after collection (15 min-
utes at 2,000 × g at 4°C) and plasma was snap frozen in
liquid nitrogen and stored at -80°C.
Renin was measured by a standard immunoradio-
metric assay (Schering SA, CIS bio international,
France). Intra- and inter-assay coefficients of variation
were 4.1% and 7.6%, respectively. Angiotensin I and II
were measured by a standard radioimmunoassay
(Peninsula Laboratories, St. Helens, UK) following C-18
Sep-Pak (Waters-Millipore) extraction of the peptide.
Intra- and inter-assay coefficients of variation were 4.6%
and 7.7%, respectively.
Statistical analysis
For blood pressure, for every subject and treatment,
measurements were first averaged per test day, and sub-
sequently averaged over two successive test days. Statis-
tical analysis of treatment effects on mean DBP and SBP
and on mechanistic parameters was performed taking
into account the study population, BP class (i.e. prehy-
pertension or stage 1 hypertension), treatment, and
interaction between treatment and BP class. Treatment
effects were investigated using 2-way ANOVA. Carry
over analysis was performed to determine whether a
carry over correction was necessary. In case no signifi-
cant carry over effect was found, the model was simpli-
fied by removing this effect. If the analysis of variance
indicated an overall treatment effect (P < 0.05), compari-
sons between treatment means were performed using a
2-sided (paired) Student’s t-test. Dichotomized scores in
the questionnaire on possible adverse-effects were ana-
lyzed using Cochran-Mantel-Haenszel statistics taking
into account multiple measurements per subject. In all
statistical tests, the null hypothesis was rejected at the
0.05 level of probability (a = 5%). All data are presented
as mean ± standard deviation (SD). Statistical analysis of
the data was carried out using the SAS statistical
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Cary, NC).
Results
Study participants
Eighty healthy subjects (48 men, 32 women) were
included with a mean age of 58 ± 8 y, body mass index
(BMI) of 26.2 ± 3.1 kg/m2, systolic/diastolic BP of 136.2
(±12.7)/84.0 (±8.8) mm Hg. Thirty-four subjects had
stage 1 hypertension with a mean systolic/diastolic BP of
147.0 (±11.7)/91.5 (±6.1) mm Hg, and 46 subjects had
prehypertension with a mean systolic/diastolic BP of
128.1 (±6.1)/78.5 (±6.1) mm Hg. Upon data analysis, pla-
cebo BP values were found to be lower than baseline
values at the time of screening. Because of this, a number
of subjects fell into a lower BP class compared to the
onset of the study. As there was no effect of treatment
order on BP decrease of either intervention, subjects
were classified as having prehypertension or stage 1
hypertension based on placebo values for further analysis
of the treatment effects. There was no significant differ-
ence between treatments concerning the number of
reclassified subjects. This procedure resulted in 26 sub-
jects having stage 1 hypertension, 44 subjects having pre-
hypertension, and 10 subjects having a normal BP
(systolic BP < 120 mm Hg and diastolic BP < 80 mm Hg).
These normotensives were excluded from further ana-
lyses, because the number of subjects was too small for a
sound evaluation. Baseline characteristics of the study
population (n = 70) are shown in Table 2. Compliance
with intake of the study substances, assessed by counting
returned capsules, was very good. Also compliance with
study procedures with respect to maintenance of habitual
diet and physical activity pattern was very good.
Blood pressure
The BP values after 4 weeks treatment are presented in
Table 3. The data indicate that in stage 1 hypertensive
subjects, MPH1 induced a significant lowering of systo-
lic BP by 3.8 mm Hg (P = 0.0080) and of diastolic BP
by 2.3 mm Hg (P = 0.0065) compared with placebo. In
subjects with prehypertension, the differences in systolic
BP and diastolic BP between MPH1 and placebo were
not significant. MPH2 did not change BP significantly as
compared with placebo in either stage I hypertensives or
prehypertensives.
Safety parameters
Intake of both MPHs was well tolerated. No significant
differences in clinical laboratory parameters and adverse
events were observed between placebo and MPHs.
Thirty seven subjects reported a adverse effect after
intake of the placebo (in total 118 occurrences of
adverse effects), 43 subjects reported a adverse effect
after intake of MPH1 (in total 126 occurrences of
adverse effects), and 37 subjects reported a adverse
effect after consumption of MPH2 (in total 114 occur-
rences of adverse effects). Most reported symptoms
occurred ‘hardly ever’ or ‘sometimes’. In single occa-
sions, a symptom occurred ‘often’ or ‘very often’, but no
clear differences were observed between treatments.
Adverse effects most often reported were flatulence,
headache, dry mouth, and fatigue. Only flatulence was
significantly more often reported after placebo treatment
(23×) compared with MPH1 (16×; P = 0.0196) and
MPH2 (14×; P = 0.0339) (Figure 1). Since the frequency
and seriousness of the reported adverse effects was low,
the above mentioned differences between MPHs and
placebo were not considered clinically relevant.
Mechanistic parameters
No significant differences between MPHs and placebo
treatment were found in plasma renin activity or concen-
trations of angiotensin I and II (Figure 2). In all subjects,
intake of the placebo, MPH1, and MPH2 for 4 weeks
resulted in similar mean renin activities. Mean angioten-
sin I and II concentrations after intake of placebo were
comparable with those after intake of MPH1 and MPH2.
Discussion
In subjects with stage 1 hypertension, daily intake of
MPH1, delivering 15 mg IPP, for 4 weeks lowered
Table 2 General characteristics of the study population
1
Parameter Stage 1 hypertension Prehypertension
Number of subjects 26 44
Male 17 26
Female 9 18
Age (years) 59.0 ± 7.3 57.5 ± 9.1
Body weight (kg) 82.7 ± 13.8 82.0 ± 12.5
Height (m) 1.8 ± 0.1 1.8 ± 0.1
BMI (kg/m
2) 26.5 ± 3.4 26.2 ± 3.2
Diastolic BP (mmHg) 89.2 ± 10.1 82.4 ± 7.0
Systolic BP (mmHg) 148.7 ± 11.5 130.3 ± 8.3
1 Data are presented as mean ± SD.
Table 3 Blood pressure measurements in subjects with
stage 1 hypertension and in subjects with
prehypertension after daily intake of a placebo, or MPH
1 or MPH 2 for 4 weeks
1
Stage 1 hypertension Prehypertension
Systolic BP Diastolic BP Systolic BP Diastolic BP
Placebo 150.4 ± 8.9 92.0 ± 8.5 128.4 ± 5.1 80.4 ± 4.8
MPH 1 146.6 ± 10.8* 89.7 ± 8.7* 130.0 ± 8.1 81.1 ± 6.2
MPH 2 149.9 ± 10.0 92.0 ± 7.8 128.9 ± 8.4 81.2 ± 6.2
1 Data are presented as mean ± SD; * denotes significant difference vs.
placebo.
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Hg compared with placebo. Daily intake of MPH2 con-
taining 13.2 mg MAP, 4.6 mg LPP, and 3.7 mg IPP did
not affect BP in these subjects. Since MPH1 contains
primarily IPP while MPH2 contains mainly MAP and
LPP, this differential effect despite equal protein dose of
the two treatments suggests superiority of IPP over the
other peptides for BP lowering, or even functional
antagonism of MAP and LPP against IPP (i.e. MAP and
LPP having an opposite effect compared to IPP in vivo).
Alternatively, MAP and LPP may be less bioavailable
than IPP. The bioavailability of IPP has been
demonstrated in humans [25], but bioavailability data
for MAP and LPP are lacking.
In our study MPHs were given for a period of
4 weeks. A further lowering of BP might have been
achieved in a longer treatment periods as has been
shown in studies on comparable products [27-30].
In subjects with prehypertension, daily intake of both
MPH1 and MPH2 did not affect BP. Also in other stu-
dies, lactotripeptides, in particular VPP and IPP, appear
more effective in reducing BP of subjects with a higher
starting BP (Sano et al, 2005; Aihara et al, 2005). Indeed,
in none of the trials with normotensives were any
Figure 1 Frequency of reported adverse effects after intake of placebo (white bars) or MPH1 (black bars) or MPH2 (grey bars) for
4 weeks; * significantly different from placebo, P < 0.05.
Figure 2 Plasma renin activity and angiotensin 1 and 2 concentrations (mean ± SEM) in stage 1 hypertensive subjects (S1H, n = 26)
and prehypertensive subjects (PH, n = 44) and after intake of placebo (white bars) or MPH1 (black bars) or MPH2 (grey bars) for 4
weeks.
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in line with findings in studies using pharmaceutical
interventions [35].
In many papers, BP reduction through lactotripeptides
has been suggested to be due to inhibition of the renin-
angiotensin system, which plays an important role in
regulating arterial pressure. Renin converts angiotensi-
nogen to the biologically inactive angiotensin I, which in
turn undergoes proteolytic cleavage by ACE to the vaso-
constrictor angiotensin II [36]. Inhibition of ACE leads
to an increase of the angiotensin I/angiotensin II ratio
and a subsequent compensatory increase in renin activ-
ity. We could not demonstrate any effects of either
MPH on renin activity, angiotensin I and II. Although
local ACE inhibitory effects near the vascular wall may
be overlooked by measuring angiotensin in blood sam-
ples from the systemic circulation, these findings do not
support an angiotensin-mediated effect of ACE inhibi-
tion in vivo. This may explain why the in vitro ACE
inhibitory potency of MPH1 and MPH2 did not predict
their BP lowering activity. Indeed, based on their IC50
values, MPH2 was expected to lower BP more than
MPH1, but the contrary was found in this study.
An alternative way in which ACE inhibition could be
involved in the observed BP effects would be through an
increased availability of the endogenous vasodilator bra-
dykinin [37]. Alternative mechanisms, such as such as
opioid-like activities, inhibition of the release of the
vasoactive substances such as the vasoconstrictor
endothelin-1, eicosanoids and nitric oxide have been
proposed to underlie the blood pressure lowering effect
of lactotripeptides (see [38] for a review). Further work
is needed to better characterize these mechanisms.
Since lactotripeptides are frequently taken in a dairy
drink or a similar vehicle, it is often unclear whether the
blood pressure lowering effects are solely due to the lac-
totripeptides, or whether minerals in these drinks con-
tribute to the blood pressure lowering effects as well. In
the current study, the lactotripeptides have been admi-
nistered in capsules rather than in dairy drinks. Also,
MPH1 contains very few minerals (1.1 mg K
+ +C a
2+
per mg IPP) compared to other products that have been
administered in capsules in other studies (2.3 - 3.6 mg
K
+ +C a
2+ per mg IPP) [28,31,33,39]. Therefore, it is
very unlikely that minerals have contributed to the
observed blood pressure lowering effect.
The doses of MPH used in this study did not exert
any significant effects on blood and urine parameters,
adverse events, and other adverse effects, and were thus
considered safe. Previous studies confirmed that even
high daily dosages of VPP and IPP were safe
[10,31,33,34,39].
The BP reductions found for MPH1 are in the order
of magnitude of those that can be achieved by lifestyle
modifications, such as weight loss in overweight subjects
[40], regular aerobic exercise [41,42], adjustment of diet-
ary habits [43], and moderation of alcohol consumption
[44]. Cook and co-workers [45] and Whelton and co-
workers [41] investigated the impact of small reductions
in the population distribution of diastolic BP, such as
those found in our study and those potentially achieved
by lifestyle modification, on incidence of cardiovascular
heart disease and stroke. Cook estimated that a 2 mm
Hg reduction in the population average of diastolic BP
for white US subjects aged 35-64 y would result in a
17% decrease in the prevalence of hypertension, a 15%
r e d u c t i o ni nt h er i s ko fs t roke, and a 6% reduction in
the risk of coronary heart disease.
Conclusions
MPH1, an IPP-rich milk protein hydrolysate, is safe and
exerts relevant BP lowering effects in subjects with stage
1 hypertension. It may be included in lifestyle changes
aiming to prevent or reduce high BP.
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